Summit Therapeutics Inc. (SMMT)
NGM – Real vaqt narxi. Valyuta: USD
18.95
+0.29 (1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NGM – Real vaqt narxi. Valyuta: USD
18.95
+0.29 (1.55%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Summit Therapeutics Inc., biotexnologik kompaniya, bemorlar, shifokorlar, parvarishlovchilar va jamiyat uchun qulay dori vositalarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning yetakchi ishlanma nomzodi ivonescimab hisoblanadi, bu immunoterapiya uchun bispesifik antitel bo'lib, PD-1 blokirovkalash va kichik hujayrali bo'lmagan o'pka rakini (NSCLC) va kolorektal rakni (CRC) davolash uchun anti-angiogenez bilan birgalikda ishlaydi. Kompaniya, shuningdek, ivonescimabni kimyoterapiya bilan birlashtirgan, bu epidermal o'sish omilining retseptor mutatsiyali, mahalliy rivojlangan yoki metastatik bo'lmagan skuamoz bo'lmagan NSCLC bemorlari uchun III bosqich klinik sinovda; birinchi qator metastatik NSCLC; va birinchi qator rezektsiya qilinmaydigan metastatik CRC uchun. Kompaniya o'z mahsulotlarini Qo'shma Shtatlar, Kanada, Yevropa, Yaponiya, Lotin Amerikasi, Yaqin Sharq va Afrikada sotadi. Kompaniya 2003 yilda tashkil etilgan va shtab-kvartirasi Mayami, Florida shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allen S. Yang M.D., Ph.D. | Head of R&D Strategy |
| Dr. Laura Q. M. Chow M.D. | Senior Vice President of Clinical Development |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer |
| Dr. Wang Clow Fong ScD | Chief Biometrics Officer |
| Mr. Bhaskar Anand | Chief Accounting Officer |
| Mr. Dave Gancarz | Chief Business & Strategy Officer |
| Mr. Nathan LiaBraaten | Senior Director of Investor Relations |
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-Q | smmt-20260331.htm |
| 2026-04-17 | DEFA14A | smmt-20260417.htm |
| 2026-04-17 | ARS | summittherapeuticsinc_x202.pdf |
| 2026-04-06 | PRE 14A | smmt-20260406.htm |
| 2026-02-23 | 8-K | smmt-20260223.htm |
| 2026-02-23 | 10-K | smmt-20251231.htm |
| 2026-01-29 | 8-K | smmt-20260129.htm |
| 2026-01-12 | 8-K | smmt-20260112.htm |
| 2025-11-07 | 8-K | smmt-20251107.htm |
| 2025-10-29 | S-3ASR | d79902ds3asr.htm |